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Epstein-Barr virus (EBV) gene expression in nasopharyngeal carcinoma (NPC) includes abundant right-
ward transcription of the BamHI A fragment, consisting of mRNAs ranging in size from approximately 4.0 to
8.0 kb. These transcripts include several distinctly spliced forms which are 3*-end coterminal and contain the
BamHI A rightward frame 0 (BARF0) open reading frame (ORF) in the final exon. BamHI A transcription is
detected at a lower level of expression in EBV-infected lymphoid cells. In this study, cDNA cloning, reverse
transcription-based PCR, and Northern (RNA) blotting were used to further define the structures of the
BamHI A transcripts and to characterize their expression in different EBV-infected tissues. Three BamHI A
cDNAs isolated from a passaged NPC represent previously unidentified mRNAs that contain BARF0 and
additional ORFs encoded by multiple exons, including one which extends the size of the BARF0 ORF from 174
to 279 codons. The distinct exons were detected in multiple, differently sized mRNAs, indicating that these
transcripts have complex patterns of alternate splicing. In support of this finding, 5*-end analysis confirmed
the presence of a previously reported start site and also identified a subset of transcripts of 4.8 kb and larger
that initiate further 5* to this site. In addition, 3*-end analysis identified heterogeneous 3*-end processing in
all of the BamHI A mRNAs, resulting in transcripts that either contain the entire BARF0 ORF or are cleaved
and polyadenylated 5* of the stop codon. Finally, the expression of multiple, distinctly spliced BamHI A
transcripts was consistently detected in a wide range of EBV-infected samples, including NPC, Burkitt’s
lymphoma, and parotid carcinoma biopsy samples, and in type I and type III Burkitt’s lymphoma lines and
type III lymphoblastoid cell lines. This complex pattern of start site selection, alternate splicing, and hetero-
geneous 3*-end processing is likely to regulate the expression in vivo of the ORFs encoded by the EBV BamHI
A transcripts.
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus
that likely plays a causative role in the development of several
cancers. It is consistently detected in endemic Burkitt’s lym-
phoma (BL) and nasopharyngeal carcinoma (NPC). Analysis
of viral termini indicates that both BL and NPC are clonal
proliferations of a single EBV-infected cell, suggesting that the
virus has a role in the origin of these tumors (8, 26, 32). It is
therefore important to identify the viral genes which are ex-
pressed in these transformed cells.
In vitro, EBV infection of B lymphocytes efficiently results in
the outgrowth of immortalized lymphoblastoid cell lines
(LCLs) (25, 31). This infection is predominantly nonproduc-
tive, with expression of six nuclear antigens (EBNAs), three
membrane proteins (LMP1, -2A, and -2B), and two highly
abundant small nuclear transcripts (EBER1 and -2) (17). This
pattern of EBV gene expression has been defined as type III
latency, whereas in BL, viral gene expression is more restricted
and has been defined as type I latency (16). In BL in vivo, only
EBNA-1 has been detected at the protein level. In NPC, de-
fined as type II latency, EBNA-1 has been detected by immu-
noblotting in all samples, and LMP1 has been detected in 40 to
60% (9, 36). Studies of viral transcription in NPC by Northern
(RNA) blotting, cDNA cloning, and reverse transcription-
based PCR (RT-PCR) have also detected the EBER1 and
EBER2 polymerase III RNAs, LMP1 and LMP2 mRNAs, and
rightward transcription terminating in the BamHI A region of
the EBV genome (6, 11, 33).
Transcription from BamHI A was not initially detected in
latently infected LCLs and was first identified in NPC, in which
these transcripts are relatively abundant. The initial studies
identified several rightward messages, ranging in size from
approximately 4.0 to 8.0 kb, on Northern blots (12, 13). These
transcripts have subsequently been detected by RT-PCR at
very low levels in LCLs (3, 7, 15). In situ hybridization has
detected BamHI A transcription in all cells of NPC tumors, in
the nude-mouse-passaged NPC C15, and in a carcinoma of the
parotid gland. The transcripts have also been detected at low
levels in B cells maintained in vitro, including cell lines with
type 1 latency in which only the EBNA-1 gene was thought to
be expressed (3, 11). BamHI A transcription is therefore a
significant component of EBV latent gene expression, and it is
essential to determine the structures of these mRNAs.
Several partial BamHI A cDNAs have been isolated from
different sources, including NPC, C15, and EBV-induced lym-
phomas of cottontop tamarins (7, 12, 13, 15, 49). These cDNAs
are distinctly spliced but 39-end coterminal, and all include a
174-codon open reading frame (ORF) designated BamHI A
rightward frame 0 (BARF0). This ORF has been translated in
vitro and is immunoprecipitable with sera from patients with
NPC, suggestive of its expression in vivo (11). Other unique
ORFs have been identified in certain BamHI A cDNAs (15). It
has also been suggested that the BamHI A transcripts have a
role in the maintenance of latency by an antisense regulation of
the replicative genes encoded by the opposite strand (13). In
this regard, the BamHI A transcripts are analogous to the
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latency-associated transcripts of herpes simplex virus that also
contain sequences that are antisense to replicative genes. Al-
though the structures of the larger latency-associated tran-
scripts are still unknown, these transcripts potentially encode a
number of small ORFs. A regulatory role for these RNAs has
not been established; however, the expression in vivo of one of
the ORFs has recently been described (21).
In this study, cDNA cloning, RT-PCR, and Northern blot
hybridization were used to define the structures of the BamHI
A transcripts and to characterize their expression in different
EBV-infected tissues. cDNA clones isolated from C15 con-
tained novel exons and distinct patterns of alternate splicing.
These cDNAs represent previously unidentified mRNAs that
contain BARF0 and additional ORFs encoded by multiple
exons, including one which extends the size of the BARF0
ORF from 174 to 279 codons. The expression of the distinct
mRNAs represented by these cDNAs, and of previously re-
ported BamHI A cDNAs, was consistently detected in NPC,
BL, and parotid carcinoma biopsy samples, in type I and type
III BL lines, and in a type III LCL. The cDNAs presented here
and elsewhere now identify at least five distinct patterns of
splicing for the BamHI A transcripts. Four of these splicing
patterns were detected in multiple size-selected mRNA frac-
tions, indicating additional levels of transcript heterogeneity
and patterns of alternate splicing. In support of this finding,
59-end analysis of the BamHI A transcripts confirmed the
presence of a previously reported start site and also identified
a subset of transcripts of 4.8 kb and larger that initiate further
59 to this site. In addition, 39-end analysis identified heteroge-
neous 39-end processing in all of the BamHI A mRNAs, re-
sulting in transcripts that either contain the entire BARF0
ORF or are truncated upstream of the stop codon. This com-
plex pattern of start site selection, alternate splicing, and 39-
end processing is likely to regulate the expression in vivo of the
ORFs encoded by the EBV BamHI A transcripts.
MATERIALS AND METHODS
Cell lines and tumors. Cell lines were grown at 378C in RPMI 1640 medium
with 10% fetal calf serum and antibiotics. B95-8 is an EBV-positive marmoset
LCL. Raji, Akata, and Mutu are EBV-positive BL cell lines. B95-8 and Raji have
type III latency, while Akata and Mutu have type I latency (36). Louckes is an
EBV-negative BL cell line. NPC tumors C15, C17, C18, and C19 were serially
passaged in athymic nude mice and have been previously described (5, 6). C15
tumors were passaged by using Matrigel basement membrane matrix (Collabo-
rative Biomedical Products). Biopsies were obtained as frozen samples and
stored at 2708C.
RNA preparation and Northern blotting. Total RNA was prepared by sus-
pending pelleted cells or pulverized frozen specimens in 4 M guanidine thiocy-
anate and then subjecting them to centrifugation through a 5.7 M cesium chlo-
ride step gradient (12). Poly(A)1 RNA (mRNA) was prepared by oligo(dT)-
Sepharose chromatography (Collaborative Biomedical Products) or by using
Oligotex-dT (Qiagen) according to the manufacturer’s instructions. For North-
ern blots, 30 mg of poly(A)1 RNA was resolved by electrophoresis on 1%
agarose formaldehyde gels with RNA molecular weight standards (Life Tech-
nologies) and blotted by capillary transfer onto BA-S85-supported nitrocellulose
(Schleicher & Schuell) (11). 32P-labeled single-stranded RNA probes were pre-
pared from linearized templates by using bacteriophage RNA polymerases and
purified by using Sephadex G-50 quick-spin RNA columns (Boehringer Mann-
heim). Hybridizations were performed at 508C, using $106 cpm/ml in 50%
formamide, with washing at 728C in 0.13 SSC (13 SSC is 0.15 M NaCl plus 0.015
M sodium citrate)–0.1% sodium dodecyl sulfate (SDS)–0.1% sodium pyrophos-
phate.
For preparation of size-selected mRNA fractions, 40 to 50 mg of C15 poly(A)1
RNA was resolved by electrophoresis on 1% agarose denaturing gels. Fraction
size was determined by comparison with RNA molecular weight standards (Life
Technologies) and by hybridization of a parallel lane which was blotted and
probed with a single-stranded RNA probe complementary to BARF0. RNA was
extracted from gel slices by using an RNaid RNA purification kit (Bio 101).
RT-PCR was performed by using Superscript II reverse transcriptase (Life Tech-
nologies) and 0.5 mg of oligo(dT)20 primer for each fraction as described below.
RT-PCR and cDNA cloning. Two-microgram RNA samples were denatured by
using 10 mM methylmercuric hydroxide (Alpha Chemical) for 10 min at room
temperature, and then 0.14 M 2-mercaptoethanol was added. Oligo(dT)20
primer (0.5 mg) was annealed by heating to 708C for 10 min and then incubated
on ice. Reverse transcription was performed in a 20-ml reaction volume at 458C,
using Superscript II reverse transcriptase (Life Technologies) according to man-
ufacturer’s instructions. Equivalent aliquots of RNA were processed in parallel
without the addition of reverse transcriptase to serve as negative controls.
PCR was performed with 5 ml of a 1:20 cDNA dilution in a 25- or 50-ml
reaction volume with Taq DNA polymerase (Promega), using standard reaction
conditions including 1.5 mM MgCl2, 0.5 pmol of each primer per ml, 200 mM
dATP, dCTP, and dTTP, 50 mM dGTP, and 150 mM 7-deaza-dGTP (Boehringer
Mannheim) for 40 cycles. Reaction conditions were as follows: 958C for 5 min,
608C for 1 min, and 728C for 1 min for 1 cycle; 958C for 1 min, 608C for 1 min,
and 728C for 1 min for 39 cycles; and 728C for 10 min. Nested PCRs were
performed with a 1:50 template dilution for 20 to 40 cycles. PCR assays included
negative control reaction mixtures containing no cDNA. Twenty microliters of
each PCR reaction mixture was resolved by electrophoresis on 1% agarose gels
with DNA molecular weight size standards. Gels were denatured, neutralized,
and blotted by capillary transfer onto BA-S83-supported nitrocellulose (Schlei-
cher & Schuell) (12). Hybridizations were performed at 458C, using 32P-end-
labeled oligonucleotides at $106 cpm/pmol/ml and washed at 458C in 13 SSC–
0.1% SDS.
PCR primers and oligonucleotide probes (Table 1) are numbered at their 59
ends according to the B95-8 sequence, except for primers within the 12-kb B95-8
deletion, which are numbered according to Raji sequence, and extend 59 to 39 in
the direction indicated (R, rightward; L, leftward) (1, 28).
For cloning of PCR products, ethidium bromide-stained bands were extracted
from agarose gels by using Qiaex (Qiagen), treated with T4 DNA polymerase
and T4 polynucleotide kinase (Promega), and ligated into the pBS vector (Strat-
agene). Positive clones were identified by Southern blotting of plasmids digested
with restriction enzymes, and an example of each distinctly sized insert was
sequenced.
5* RACE. Rapid amplification of cDNA 59 ends (59 RACE) was performed as
previously described (10). Two micrograms of poly(A)1 RNA was primed with
0.5 mg of oligo(dT)20 and reverse transcribed as described above. cDNA 59 ends
were tailed with dATP and terminal deoxynucleotidyltransferase (Boehringer
Mannheim) according to the manufacturer’s instructions. PCR was performed
with an oligo(dT)17-adapter primer (59 GACTCGAGTCGACATCGAT17) and
leftward gene-specific primer 9983-L (exon III) or 6572-L (exon II), using stan-
dard conditions as described above. PCR products were screened by Southern
blot analysis using oligonucleotide probe 150708-L. For cloning, gel slices cor-
responding to hybridizing bands were extracted by using Qiaex (Qiagen) and
cloned by treatment with T4 DNA polymerase and T4 polynucleotide kinase
(Promega) prior to ligation into plasmid vector pGem3Z (Promega).
3* RACE. Rapid amplification of cDNA 39 ends (39 RACE) was performed as
previously described (10). Two micrograms of poly(A)1 RNA was primed with
oligo(dT)17-adapter (59 GACTCGAGTCGACATCGAT17) and reverse tran-
scribed as described above. PCR was performed with primer 160853-R and an
adapter region primer (59 GACTCGAGTCGACATCGAT), and products were
screened by Southern blot analysis using oligonucleotide probe 160901-R. For
cloning, gel slices corresponding to hybridizing bands were extracted by using
Qiaex (Qiagen) and cloned by treatment with T4 DNA polymerase and T4
polynucleotide kinase (Promega) prior to ligation into pBS1 vector (Stratagene).
39 RACE analysis of size-selected mRNA fractions was performed by PCR of
oligo(dT)20-primed, size-selected C15 cDNA fractions (see above), using primers
160853-R and oligo(dT)17-adapter (59 GACTCGAGTCGACATCGAT17). PCR
products were extracted with phenol-chloroform and precipitated. Equivalent
aliquots were subsequently cut with restriction enzyme MseI or uncut and re-
solved by electrophoresis on 10% polyacrylamide gels. Gels were transferred by
electroblotting onto Zeta-probe (Bio-Rad) and hybridized according to the man-
ufacturer’s instructions with 32P-end-labeled oligonucleotide 160901-R.
RESULTS
Cloning of alternately spliced cDNAs. In C15 and NPC
biopsy samples at least four rightward messages from BamHI
A, ranging in size from 4.0 to 8.0 kb with a prominent band at
4.8 kb, are detected on Northern blots. A similar pattern of
transcription is detected at a lower level of expression in EBV-
infected lymphoid cells. Several partial cDNAs representing
distinctly spliced, rightward BamHI A transcripts have been
previously isolated from C15 and NPC cDNA libraries (7, 12,
13, 15, 49). Structures based on the assembly of partial cDNA
sequences have been proposed to represent the major 4.8-kb
BamHI A transcript. These include a seven-exon form and an
alternate form in which exon III is spliced into exons IIIa and
IIIb (Fig. 1) (43). In this study, additional BamHI A cDNAs
containing novel exons and distinct patterns of alternate splic-
ing were isolated.
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cDNA BK1 was isolated by RT-PCR of C15 mRNA, using
primers 157313-R (exon VI) and 160537-L (exon VIIb, down-
stream of the BARF0 start codon), and contained a splice
pattern similar to that of the A73 cDNA, from an NPC biopsy,
and identical to that of the T13 cDNA from an EBV-induced
tamarin lymphoma (7, 49). cDNAs 22.2, BK1, and c25a have
therefore identified three distinct forms of exon VII in NPC,
all of which encode the BARF0 ORF (Fig. 1). In addition, BK1
encodes a 96-codon ORF that is not present in the A73 cDNA
because of a 1-bp difference at the splice donor site of exon VI
(see below).
Additional BamHI A cDNAs were isolated by RT-PCR us-
ing primer 9942-R (exon III), within the BamHI I1 fragment,
and 159190-L (exon VIIa). cDNA RB2 contained the previ-
ously identified exons IIIa, IIIb, IV, and VI but had a distinctly
spliced form of exon V (forming exons Va and Vb) (Fig. 1). To
determine if the RB2 cDNA was derived from a transcript that
contains the BARF0 ORF, RT-PCR was performed with prim-
ers 9942-R (exon III) and 160537-L (exon VIIb, downstream of
the BARF0 start codon). This resulted in detection of a prod-
uct of a predicted size (1,119 bp) which was identified by
hybridization with an internal oligonucleotide probe (160387-L,
exon VIIb), indicating that the RB2 cDNA was derived from a
transcript that contains exons VIIa and VIIb (Fig. 1 and data
not shown). This result, and the identical structures of exons
VI and VIIa in RB2 and BK1, indicated that these cDNAs are
likely derived from the same spliced transcript, which is re-
ferred to hereafter as RB2/BK1. This transcript would encode
BARF0 as well as a 57-codon ORF spanning exons IIIa and
IIIb, and a 126-codon ORF (spanning exons Vb to VIIa) that
is an in-frame extension of the 96-codon ORF of BK1 (Fig. 2).
As noted above, this ORF is not encoded by the A73 cDNA
because of the different splice donor site of exon VI. To further
analyze this distinction and to ensure that it was not the result
of a misincorporation by Taq polymerase, three additional
cDNAs from C15 and three cDNAs from an NPC biopsy were
cloned by RT-PCR using primers in exon VI (157313-R) and
FIG. 1. Structures of the C15 BamHI A cDNAs. cDNAs isolated from the
C15 passaged NPC are positioned as exons (thick lines, roman numerals) and
introns (thin lines) aligned with the BamHI restriction map of Raji strain EBV
sequence. Splice sites are numbered according to the B95-8 EBV sequence,
except for exons II and III, which are numbered according to the Raji insertion
relative to B95-8 in this region (1, 28). The position of BARF0 is also indicated.
The seven-exon structure (4.3 kb [22.2]) was assembled from two overlapping
cDNAs, and the alternately spliced exon IIIa-IIIb structure was derived from a
third cDNA (43). c25a has also been previously reported (12). BK1, RB2, RB3,
and RK1 were isolated by PCR amplification of C15 cDNA by using primers
157313-R and 160537-L for BK1, 9942-R and 159190-L for RB2 and RB3, and
9942-R and 160537-L for RK1. BK1 is spliced identically to the T13 cDNA
isolated from an EBV-induced tamarin lymphoma (49). The unshaded exon
regions are inferred by PCR analysis to be contained in the full-length transcripts
(see Results).
TABLE 1. Oligonucleotides used for PCR and hybridizationa
Oligonucleotide Sequence Location
150195-R 59 CTGCATGCGCAAGGGTCACA Exon I
150400-R 59 AACTCTGCAGGTGAGATTCA Exon I
150519-R 59 GAGTCATTCCTAAACTGTCA Exon I
150626-L 59 CGGGTATGGCTGTTGTTGCA Exon I
150708-L 59 TCCATGTTGCTGAGGAGCT Exon I
6572-L 59 GCCCCCGTTTCCAGTTC Exon II
9942-R 59 TGTGAATACGGGCGTATGAC Exons III and IIIa
9983-L 59 AGCACACGCCCCCATTTCTA Exons III and IIIa
10311-R 59 CCGTAAAGTAGCGGCTGCCG Exons III and IIIb
10350-L 59 TCCTTCAACAGCACCACCTA Exons III and IIIb
156051-R 59 GTTGGCCTCAAAGATCCGAC Exons V and Va9
156180-L 59 CCGTTCCATTATGGGCTACG Exons V and Va9
157313-R 59 GTTTTGCGCCTGGAAGTTGT Exon VI
157375-L 59 CGTGCCTCCAACGTCTTTGA Exon VI
159190-L 59 AGCTTTCCTTTCCGAGTCTG Exons VII, VIIa, and VIIa9
159847-R 59 GTACTTGGAATTCTCAAAGG Exons VII and VIIa9
160004-R 59 TCTCGCTCTGTTGCGCCAGG Exons VII and VIIa9
160070-R 59 ACTGCTCCTTGCGCTTGAGC Exon VII; intron VIIa9-VIIb
160387-L 59 GGCTGACTCACCTGTTTG Exons VII, VIIb, and VIIb9
160537-L 59 AGCTCCTCTATTGGAACTCT Exons VII, VIIb, and VIIb9
160853-R 59 GCACAGAGGTGATGTAGA Exons VII, VIIb, and VIIb9
160901-R 59 GAAAGCGGCCCAGCAGATCC Exons VII, VIIb, and VIIb9
a Oligonucleotides are numbered at the 59 end according to the EBV strain B95-8 sequence or Raji sequence (exons II and III only) and extend in the direction
indicated (R, rightward; L, leftward) relative to the standard EBV genome (1, 28). The locations of oligonucleotides within the structures of the BamHI A cDNAs are
indicated.
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exon VIIb (160387-L) and sequenced. All six cDNAs were
spliced identically to the RB2/BK1 cDNA, suggesting that this
is the predominant form of the transcripts.
cDNA RB3, also isolated from C15 by using primers 9942-R
(exon III) and 159190-L (exon VIIa), contained exons III and
IV spliced directly to exon VIIa, excluding exons V and VI
(Fig. 1). To determine if the RB3 cDNA was derived from a
transcript that contains the BARF0 ORF, RT-PCR was per-
formed with primers 10310-R (exon III) and 160537-L (exon
VIIb). This resulted in detection of a product of a predicted
size (583 bp) which was identified by hybridization with an
internal oligonucleotide probe (160387-L, exon VIIb), indicat-
ing that the RB3 cDNA was also derived from a transcript that
contains exons VIIa and VIIb. This transcript would encode
BARF0, as well as a 51-codon ORF in exon III, and a 69-codon
ORF spanning exons IV, VIIa, and VIIb (Fig. 2).
cDNA RK1 was isolated from C15 by using primers 9942-R
(exon III) and 160537-L (exon VIIb, downstream of the
BARF0 start codon) and contained exons IIIa, IIIb, and IV
and distinct forms of exon V (Va9) and exon VII (VIIb9) (Fig.
1). Interestingly, exon Va9 contains an initiation codon and
coding sequences that extend the size of the BARF0 ORF
from 174 to 279 codons and would encode a protein of ap-
proximately 30 kDa (Fig. 2). Both RB2/BK1 and RK1 utilized
the same exon V splice acceptor site at bp 155725, distinct from
that for the 22.2 cDNA. Therefore, neither RB2/BK1 nor RK1
encoded the previously reported 71-codon ORF of c22.2, des-
ignated RPMS1, that spans exons IV and V in this cDNA (15).
In RK1, however, this splice created a 103-codon ORF in an
alternate reading frame (Fig. 2).
These additional cDNAs indicate that the multiple BamHI
A mRNAs are transcribed with additional exons and splicing
patterns and with alternate splicing of exons III, IV, VI, VIIa,
and VIIb. This complex pattern of transcription results in a
number of previously unidentified ORFs that could be ex-
pressed during latent infection. The use of common splice
donor and acceptor sites to generate distinct splicing patterns
indicates that the variation in the cDNA structures accurately
reflects the mRNA sequence and does not represent variation
generated in the amplification and cloning process.
Splicing patterns of BamHI A transcripts. The cDNAs iden-
tified in this study reveal that at least five distinctly spliced
mRNAs comprise the BamHI A family of transcripts (Fig. 1,
cDNAs 22.2, 25a, RB2/BK1, RB3, and RK1). All of these
cDNAs represent transcripts that include the BARF0 ORF in
the final exon, suggesting that this ORF may be an important
component of BamHI A mRNA expression. Nevertheless,
given that the cDNAs also encode unique ORFs that may also
be expressed, it is important to determine which of these
cDNAs represents the abundant 4.8-kb BamHI A mRNA and
which represent the larger transcripts that are detected at
lower levels. Previous studies have used exon-specific and in-
tron-specific oligonucleotide probes to determine the splicing
patterns of the BamHI A transcripts; however, these hybrid-
izations cannot distinguish the various BamHI A cDNAs which
contain large regions of sequence overlap (7, 43).
To determine the splicing patterns contained within the dif-
ferently sized transcripts detected by Northern blotting, RT-
PCR was performed with gel-purified, size-selected mRNA
fractions. C15 mRNA extracted from denaturing gels in frac-
tions corresponding to the size of bands detected by Northern
blotting (7.6, 6.2, and 4.8 kb) was used to synthesize cDNA.
PCR with primer pairs that distinguish the unique splices
within each of the BamHI A cDNAs was followed by hybrid-
ization with internal oligonucleotide probes (Fig. 3A). The
results demonstrated that each of the mRNA fractions con-
tained multiple, distinctly spliced structures, indicating that
complex patterns of alternate splicing are incorporated into
transcripts of different size.
RT-PCR of the size-selected fractions performed using
primers 159847-R (exon VIIa9) and 160387-L (exon VIIb)
produced a 370-bp spliced product and an unspliced product of
541 bp, characteristic of the c25a and 22.2 cDNAs, respectively
(Fig. 3A). By hybridization with an oligonucleotide probe
(160004-R) in exon VII/VIIa9, the spliced product was predom-
inantly detected in the 6.2-kb fraction and at a lower level in
the 7.6- and 4.8-kb fractions, while the unspliced product was
detected exclusively in the 7.6-kb fraction (Fig. 3B, probe 1).
The identity of the unspliced product was confirmed by hybrid-
ization with an oligonucleotide probe (160070-R) within the
intron of c25a (Fig. 3B, probe 2). This probe hybridized to the
541-bp unspliced product only in the 7.6-kb fraction but did not
hybridize to the 370-bp product. A low level of hybridization to
small, heterogeneous material was detected in the 6.2-kb frac-
tion. This result indicated that the 22.2 cDNA is likely derived
from a 7.6-kb BamHI A mRNA. In addition, the detection of
the unspliced form of exon VII only in the largest mRNA
fraction demonstrated that the size-selected RNA fractions
used in this study were discrete and that there was no cross-
contamination of the fractions due to degradation of larger
transcripts. Furthermore, the detection of both the unspliced
and spliced forms of exon VII in the 7.6-kb fraction indicated
that BamHI A transcription of 7.6 kb consists of at least two
differently spliced mRNAs.
RT-PCR using primers 157313-R (exon VI) and 160387-L
(exon VIIb) produced a 350-bp spliced product characteristic
of the RB2/BK1 cDNA (Fig. 3A). By hybridization with an
oligonucleotide probe (157375-R) in exon VI, this product was
detected at a very high level in the 4.8-kb mRNA fraction, at a
trace level in the 7.6-kb fraction, and not at all in the 6.2-kb
fraction (Fig. 3B, probe 3). This result demonstrated that the
splicing pattern of the RB2/BK1 cDNA is contained within
both the 4.8- and 7.6-kb mRNAs. To account for the difference
in transcript size, these transcripts probably contain the RB2/
BK1 exons alternately spliced to distinct 59 exons. This result
also demonstrated that BamHI A transcription of 4.8 kb con-
sists of at least two distinct splicing patterns (i.e., c25a and
FIG. 2. ORFs of the C15 BamHI A cDNAs. ORFs contained within each
cDNA are shown as shaded regions, with positions of the start codons numbered
as in Fig. 1. The number of amino acid codons in each ORF is indicated. The
BARF0 ORF, shown here in the RB2/BK1 cDNA, was shown by PCR analysis
to be contained in each cDNA (see Results). The 126-aa ORF of RB2/BK1 is an
in-frame extension of a 96-aa ORF in the T13 cDNA, which has been previously
described (49). In RK1, the 279-aa ORF, RK-BARF0, is an in-frame extension
of the BARF0 ORF.
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RB2/BK1). In addition, the high level of detection of the RB2/
BK1 cDNA in the 4.8-kb mRNA fraction suggests that the
RB2/BK1 cDNAmay represent a transcript that is expressed at
high levels in vivo.
Further heterogeneity in the BamHI A transcripts was de-
tected with primers 156051-R (exon Va9) and 160387-L (exon
VIIb), which resulted in amplification of a spliced product of
302 bp characteristic of the RK1 cDNA. By hybridization with
an oligonucleotide probe (156180-L) in exon Va9, this product
was detected at approximately equal levels in the 7.6-, 6.2-, and
4.8-kb fractions, as well as in a smaller 4.0 kb fraction, but not
in the negative control (Fig. 3B, probe 4). This result suggested
that the transcripts represented by RK1, and the 274-codon
RK-BARF0 ORF that it encodes, may also be expressed at
relatively high levels in vivo.
RT-PCR was also performed with primers 10311-R (exon
III) and 159190-L (exon VIIa), which amplified a spliced prod-
uct of 263 bp characteristic of the RB3 cDNA (Fig. 3A). This
FIG. 3. RT-PCR analysis of size-selected C15 RNA fractions. (A) Detection of alternately spliced BamHI A mRNAs. PCR primers (bent arrows, with genomic
coordinates), oligonucleotide probes (straight arrows, numbered 1 to 5), and sizes of predicted products used for detection of alternately spliced BamHI A mRNAs
are indicated. The primers are numbered as in Fig. 1 at the 59 ends and extend 59 to 39 in the direction indicated (R, rightward; L, leftward). (B) Southern blot
hybridizations. Hybridizations to amplified products from size-selected mRNA fractions are shown for each set of PCR primers and oligonucleotide probes depicted
in panel A. RNA fractions were excised from a denaturing gel; fraction sizes (in kilobases) were determined by comparison with RNA molecular weight standards and
by hybridization of a parallel lane with a single-stranded RNA probe complementary to BARF0 sequences. Primers 159847-R and 160387-L amplify an unspliced
product (541 bp) from c22.2 and a spliced product (370 bp) from c25a. Probe 1 hybridizes to both products, while probe 2, located within the intron of the c25a,
hybridizes only to products having the unspliced structure. The identity of the unspliced, 541-bp product of the c22.2/c25a amplification was confirmed by hybridization
of the same blot with probe 2, located within the c25a intron. Probes: 1, 160004-R; 2, 160070-R; 3, 157375-R; 4, 156180-L; 5, 10350-L. H, no cDNA (RT-PCR negative
control).
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product was detected by hybridization with an oligonucleotide
probe (10350-L) in exon III in the 7.6- and 6.2-kb mRNA
fractions but not in the smaller fractions of 4.8 and 4.0 kb (Fig.
3B, probe 5).
Finally, RT-PCR was performed with primers 157313-R
(exon VI) and 159190-L (exon VII), which amplify a product of
approximately 180 bp characteristic of the 22.2 and RB2/BK1
cDNAs. These cDNAs have predicted amplified products of
177 and 182 bp, respectively; however, this difference could not
be distinguished in this assay. These primers span an intron of
1.7 kb in these cDNAs, and the sequence within this intron has
been proposed to account for the larger size of the 6.2- and
7.6-kb transcripts (7, 43). Interestingly, however, the 180-bp
spliced product was detected by hybridization with an oligonu-
cleotide probe (157375-R) in all of the size-selected mRNA
fractions but not in negative controls (data not shown). This
result indicated that at least a subset of each of the differently
sized BamHI A mRNAs, including the larger mRNAs, do not
contain the sequences of the intron between exons VI and VII.
In summary, this analysis demonstrated the presence of het-
erogeneous populations of BamHI A transcripts within each of
the discrete, size-selected mRNA fractions. The splicing pat-
terns of certain cDNAs were detected in only one of the frac-
tions (cDNA 22.2 in the 7.6-kb fraction), in a few of the
fractions (RB3 in the 7.6- and 6.2-kb fractions and RB2/BK1 in
the 4.8- and 7.6-kb fractions), or in all of the fractions (c25a
and RK1). These results indicated the existence of complex
patterns of alternate splicing that are incorporated into tran-
scripts of different sizes. In addition, the identification of the
RB2/BK1 and RK1 splicing patterns at relatively high levels in
the major 4.8-kb mRNA fraction implicates these cDNAs, and
the ORFs that they encode, as important components of
BamHI A transcription.
5* analysis of the BamHI A transcripts. A previous study has
reported a transcriptional initiation site for the BamHI A
mRNAs and proposed that the major 4.8-kb mRNA initiates at
this site and contains the splicing pattern of the 22.2 cDNA. It
has also been proposed that the larger BamHI A mRNAs
initiate at this site but contain additional 39 sequences from
within the intron regions of the 22.2 cDNA structure. How-
ever, the existence of additional 59 start sites was considered
likely since previous studies have detected transcription only in
the intron between exons VI and VII, and, as noted above, this
intron is not present in at least a subset of the larger transcripts
(7, 43). In addition, the length of the proposed structure for the
4.8-kb mRNA was only 4.3 kb. Furthermore, the unspliced
exon VII characteristic of the 22.2 cDNA was detected only in
the 7.6-kb mRNA fraction, not in the 4.8-kb fraction, while a
subset of the transcripts of 7.6 and 6.2 kb include the relatively
short, spliced structure of the RB3 cDNA. Therefore, to con-
firm the previously reported BamHI A mRNA start site and to
determine if additional start sites exist, 59 RACE cloning,
Northern blot hybridizations, and RT-PCR-based cDNA clon-
ing were performed.
59 RACE analysis was performed by PCR amplification of
59-oligo(dA)-tailed C15 cDNA, using an oligo(dT) 59 primer
and a 39 gene-specific primer within exon II (6572-L). Three
identical cDNAs were isolated from independent amplifica-
tions and sequenced. These cDNAs were similar in structure to
a previously reported cDNA having the same exon II splice
acceptor site at bp 6514 but with an exon I splice donor site at
bp 150769 differing by 5 nucleotides (nt) from that previously
described at bp 150774 (43). 59 RACE using a 39 primer within
exon III (9983-L) contained the identical structures of exon I,
II, and III as identified in the shorter clones, differing from the
previously reported exon I donor site. All of the 59 RACE
cDNAs terminated at approximately bp 150650, in close agree-
ment with the previously reported start site (Fig. 4A).
To determine if processed transcription initiated further 59
to this site, C15 cDNA was amplified by using a 59 primer
(150519-R) located 120 nt 59 to the identified start site and a 39
primer within exon II (6572-L) or within exon III (9983-L).
The amplified cDNAs, c5.1 and c6.1, respectively, contained
the same splice patterns as the 59RACE cDNAs, but with exon
I extended unspliced to the 59 primer. This finding indicated
the existence of transcription initiating further 59 to the previ-
ously reported start site (Fig. 4A). The invariant structures of
exons I and II in the 59 RACE and RT-PCR cDNAs reported
here suggest that this region of the BamHI A transcripts is less
heterogeneous than the 39 exons.
To identify the BamHI A mRNAs that contain sequences 59
to the previously identified start site, a leftward, single-
stranded RNA probe was prepared from a clone containing the
sequences from bp 150400 to 150626 (probe 12-10; Fig. 4A)
and hybridized to a Northern blot of C15, Akata, and Louckes
(EBV-negative) mRNAs. Each lane contained 30 mg of poly(A)
RNA, and equal loading was confirmed by ethidium bromide
staining. In C15, probe 12-10 hybridized to the 4.8-kb mRNAs
and to larger transcripts, which were visible upon longer expo-
sure (Fig. 4B). Although hybridization to Akata RNA (EBV-
positive BL line) was detected with the 6.1 probe, hybridization
was not detected with probe 12-10 even upon long exposure.
This result was consistent with the greatly reduced amount of
FIG. 4. 59 analysis of BamHI A transcripts. (A) Structures of C15 59 RACE
cDNAs. cDNAs isolated by amplifying with primer 6572-L in exon II (cDNAs
1-3) or primer 9983-L in exon III (cDNA 4) are shown. cDNAs 5.1 and 6.1 were
isolated by RT-PCR of C15 mRNA, using primer 150519-R with 6572-L (c5.1)
and 150519-R with 9983-L (c6.1). The 12-10 clone, which is 59 of a previously
reported transcription start site, was isolated from C15 DNA for use in Northern
blot hybridizations (43). (B) Northern blot hybridization. Hybridization was
performed with 30 mg of poly(A) mRNA per lane from C15, Akata (AKA), an
EBV-positive BL line, and Louckes (LKE), an EBV-negative BL line, using
leftward, single-stranded RNA probes derived from cDNA 6.1 and clone 12-10.
The 12-10 probe hybridizes to messages of 4.8, 6.2, and 8.0 kb in C15.
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BamHI A transcription in Akata detected by the 6.1 probe.
Hybridization was not detected with either probe to RNA from
the EBV-negative BL line Louckes (Fig. 4B). These results
indicated that some of the larger BamHI A mRNAs in C15
initiate further 59 to the previously reported start site and also
that a subset of the 4.8-kb mRNAs contain sequences 59 to this
start site. Thus, these data demonstrated that the BamHI A
mRNAs have multiple sites of transcription initiation in NPC,
which is consistent with the identification of heterogeneous
and alternately spliced structures in these transcripts.
3* analysis of BamHI A transcripts. The 39 end of the
BARF0 ORF is unusual in that there are no recognizable
poly(A) signals located within several kilobases downstream of
the ORF. A canonical poly(A) signal (AATAAA) is located
within the ORF, 27 nt upstream of the stop codon, and a
nonconsensus poly(A) signal (ATTAAA) overlaps the stop
codon (Fig. 6A). Either of these signals could potentially direct
cleavage 39 of the BARF0 stop codon, giving rise to transcripts
encoding the entire ORF. To determine if either or both of
these signals are functional, or if a 39 cryptic polyadenylation
signal is used, cleavage sites of the BamHI A transcripts were
analyzed by 39 RACE (Fig. 5). C15, B95-8, and Raji mRNAs
were reverse transcribed by using a modified oligo(dT) primer
containing a polylinker region. The 39 ends of BamHI A tran-
scripts were amplified by PCR from these cDNAs by using 59
primer 160853-R and a 39 primer containing the polylinker
sequence. Amplified products contained sequences from the 39
end of BARF0 and from the poly(A) tail of the transcripts,
allowing determination of the transcript cleavage site.
Twelve distinct cDNAs, that could be distinguished by the
location of the cleavage site or by the length of the cloned
poly(A) tail, were isolated from the three mRNA samples (five
from C15, four from B95-8, and three from Raji). Three
cDNAs from each sample were cleaved after the adenosine at
bp 160990, 1 nt 59 to the BARF0 stop codon, resulting in
truncation of the ORF (Fig. 5B). Cleavage at this site is con-
sistent with the use of the upstream poly(A) signal within the
ORF (Fig. 5A, signal I). One cDNA from each mRNA sample
was cleaved further 39 within the four adenosine residues from
160993 to 160996. These cDNAs represent transcripts that
contain the complete BARF0 ORF and include the stop
codon. Cleavage in this region is also likely to be directed by
signal I and demonstrates heterogeneous 39-end processing of
these transcripts. A single cDNA isolated from C15 terminated
at bp 160986 and was unusual in that cleavage of the primary
transcript occurred following a cytosine nucleotide (Fig. 5B).
To determine if heterogeneous 39-end processing occurred
consistently among the differently sized BamHI A messages,
the 39 RACE protocol was modified to determine if the
BARF0 stop codon was contained only in transcripts of a
certain size. cDNAs containing the downstream cleavage site
included an MseI restriction site, TTAA, not present in those
cDNAs that exclude the BARF0 stop codon. 39 RACE was
performed with cDNA from size-selected C15 mRNA frac-
tions, and the amplified products were cut with MseI. The
presence of the MseI site resulted in the release of a 140-bp
fragment which was detected by electrophoresis on a 10%
polyacrylamide gel followed by electroblotting and hybridiza-
tion with an internal oligonucleotide probe. Transcripts con-
taining the MseI site, and therefore containing the complete
BARF0 ORF, were detected with similar frequencies relative
to the total amount of amplified product in each size-selected
fraction (Fig. 5C). These data indicated that the BamHI A
transcripts, regardless of size, undergo heterogeneous 39-end
processing. Approximately 75% of the mRNAs are cleaved
before the stop codon of the BARF0 ORF, while the remain-
der are cleaved further 39, giving rise to processed transcripts
that contain the entire ORF.
Expression of alternately spliced BamHI A mRNAs in vivo.
The BamHI A cDNAs presented in this and previous studies
represent highly spliced transcripts that contain the BARF0
ORF and encode additional, unique ORFs by virtue of their
distinct splicing patterns. Some of the splicing patterns present
in the BamHI A cDNAs have also been detected by RT-PCR
in NPC biopsies, EBV-infected B cells, and EBV-positive
LCLs (3). The primers used in the study by Brooks et al. (3),
however, did not distinguish between the splicing patterns of
the 22.2 and RK1 cDNAs or between the 22.2 and RB2/BK1
cDNAs. In this study, in order to characterize the expression in
different tissue types of the BamHI A transcripts represented
by the reported cDNAs, RT-PCR was performed with primer
pairs designed to detect the unique splicing patterns of each
cDNA (Fig. 3A). RNA was isolated from additional passaged
NPC tumors, primary-site NPC biopsies, metastatic-site NPC
biopsies, a parotid carcinoma, a BL biopsy sample, type I
(Akata and Mutu) and type III BL lines (Raji), and a type III
LCL (B95-8). Equivalent aliquots of RNA that were not re-
FIG. 5. 39 analysis of BamHI A transcripts. (A) Sequence of the 39 end of the
BARF0 ORF from position 160956. The two potential polyadenylation signals
(underlined), the TAA stop codon (overlined), and the position of the MseI
restriction site are indicated. (B) Analysis of 39 RACE cDNAs. cDNAs were
isolated from B95-8, Raji, and C15 by RT-PCR using primer 160853-R and an
oligo(dT)-adapter primer. Clones are divided into three groups according to the
locations of the cleavage site (indicated by arrow), and the number of clones in
each group from each sample is indicated. The exact cleavage site of type II
clones, which are the only clones containing the BARF0 stop codon, could not be
determined because of the run of dA in the sequence from bp 160993 to 160996.
(C) 39 analysis of size-selected C15 mRNA fractions. RNA fractions were excised
from a denaturing gel, and fraction sizes were determined by comparison with
RNA molecular weight standards and by hybridization of a parallel lane with a
single-stranded RNA probe complementary to BARF0 sequences. RT-PCR was
performed with primers 160853-R and the oligo(dT)-adapter, which amplified
products of approximately 175 bp, depending on the location of the cleavage site
and the length of amplified poly(A) tail. PCR products were cut with MseI (1)
or uncut (2), resolved by electrophoresis on a 10% polyacrylamide gel, blotted
onto nitrocellulose, and hybridized with an internal oligonucleotide probe
(160901-R). Transcripts containing the BARF0 stop codon give rise to products
that are cleaved by MseI (T/TAA), resulting in the release of a 140-bp fragment.
C15 mRNA that was not size selected (Total RNA) was included as a positive
control. A sample that contained no cDNA (H20) was also included as a negative
control for RT-PCR.
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verse transcribed were processed and amplified in parallel for
all samples as a control for false-positive signals caused by
plasmid contamination or by PCR product carryovers. Tran-
scripts represented by the c25a, RB2/BK1, RK1, and RB3
cDNAs were detected with high frequency in all tissues and
cell types (Table 2). These data demonstrated that transcripts
represented by each BamHI A cDNA were consistently ex-
pressed in both epithelial and lymphoid samples. In addition,
BamHI A transcription was demonstrated for the first time in
BL in vivo and was shown to include multiple, distinctly spliced
forms.
DISCUSSION
This study has demonstrated a complex pattern of transcrip-
tion for the BamHI A mRNAs that includes multiple start
sites, alternate splicing, and heterogeneous 39-end processing.
The analysis by RT-PCR of size-selected mRNA fractions has
provided structural information that cannot be derived from
Northern blot hybridizations used in previous studies. For ex-
ample, in a previous study, hybridization with an oligonucleo-
tide within the intron between exons IIIa and IIIb confirmed
the presence of the unspliced exon III in a transcript of 4.8 kb,
but this hybridization did not identify the exon IIIa-IIIb struc-
ture as part of these transcripts (43). In the present study, two
cDNAs which contained the spliced exon IIIa-IIIb structure
(RB2/BK1 and RK1) were detected by RT-PCR in mRNAs of
4.8 kb and in larger BamHI A transcripts. Similarly, hybridiza-
tion with an oligonucleotide probe within exon V did not
distinguish transcripts containing the unspliced exon V of the
22.2 cDNA from those containing exon Va (RB2/BK1) or exon
Va9 (RK1), and hybridization to exon VII did not distinguish
transcripts containing the unspliced exon VII of the 22.2
cDNA from those containing exon VIIa (RB2/BK1 and RB3)
or exon VIIa9 (c25a) (7, 43). In this study, the 4.8-kb mRNAs
were shown to include the Va (RB2/BK1) and Va9 exon (RK1)
as well as the VIIa9-VIIb exon structure of c25a. In contrast to
a previous study, the unspliced exon VII structure of 22.2 was
not detected in the 4.8-kb mRNAs but was present only in
transcripts of 7.6 kb (43). In addition, a previous study using an
oligonucleotide probe located within the intron between exons
II and III demonstrated hybridization to a 4.8-kb mRNA, in-
dicating that additional alternately spliced structures have yet
to be identified (7).
The 4.8-kb BamHI A mRNAs, which are the most abundant
component of BamHI A transcription, included transcripts
containing the RK1 and the RB2/BK1 cDNA structures and, at
a low level, the c25a structure. This finding suggests that the
ORFs encoded by these cDNAs are perhaps an important
component of BamHI A expression. The largest of these ORFs
are BARF0 (174 codons), present in all of the BamHI A
transcripts, RK-BARF0 (279 codons), which is an in-frame
extension of BARF0 present in RK1, a 103-codon ORF also in
RK1, and the 126-codon ORF spanning four exons of RB2/
BK1. The initiation codons of these ORFs are in a favorable
context for translation as defined by the consensus sequence
for recognition by a scanning ribosomal subunit, A/GXXA
UGG, with the exception of the RB2/BK1 126-codon ORF,
which deviates from the consensus at the 11 position (AXXA
UGA) (19). A purine at 23 is the more conserved element of
this motif in eukaryotic mRNAs, however, and in fact several
EBV genes expressed during latency, including EBNA-1, do
not conform to the consensus sequence (18). The presence of
extremely long 59 untranslated regions that would be associ-
ated with these ORFs raises the possibility that internal ribo-
some binding rather than scanning might contribute to their
efficient translation. Internal ribosome binding has been iden-
tified in picornavirus, cowpea mosaic virus, and certain cellular
mRNAs (24, 29, 46).
Previously, sequence homology has been noted between
BARF0 and the herpes simplex virus type 1 (HSV-1) ICP4
(IE175) protein consisting of 38% homology (20% identical
and 18% similar residues) over a region of 178 codons (7).
However, since similar levels of sequence homology are iden-
tifiable between this region of BARF0 and several other re-
gions of ICP4, it is unlikely that this reflects functional homol-
ogy between the two proteins. Likewise, the 103-codon ORF of
RK1 is 66% similar (26% identical) to HSV-1 ICP4 over 94
codons yet 73% similar (34% identical) over 92 codons to the
HSV-1 large tegument protein, UL36. No striking sequence
homologies to known proteins were detected by examination
of the BamHI A ORFs by using the Genetics Computer Group
sequence analysis software package (Genetics Computer, Inc.).
As has been previously noted, the BARF0 ORF is arginine
rich (25 of 174 residues, 14 mol%), containing charged resi-
dues clustered in several regions of the ORF (12). Arginine-
rich motifs (ARMs) mediate RNA binding in a number of viral
and cellular proteins and consist of a highly basic stretch of 10
to 12 amino acid residues (4). An 11-amino-acid (aa) consen-
sus sequence, which allows up to four mismatched residues,
identifies this motif in the known ARM-containing, RNA-
binding proteins. For example, adenovirus type 2 E4 protein
differs from the consensus at two residues, while human im-
munodeficiency virus type 1 Tat differs at four residues (22).
The hepatitis delta virus antigen contains two ARMs which
differ from the consensus at four and six residues, respectively
(23). Interestingly, within a 75-aa segment of the BARF0 ORF
are three 11-aa regions (two of which overlap) that differ from
the consensus ARM sequence at four residues and a fourth
region that differs at five residues. This raises the possibility
that the function of the putative BARF0 protein may involve
an interaction with viral or cellular RNAs. Other ORFs of the
BamHI A cDNAs are similarly arginine rich, most notably the
103-codon ORF of RK1 (22 mol% arginine), but none con-
tains a region having less than five mismatches to the ARM
consensus sequence.
The RK-BARF0 ORF contained within the RK1 cDNA
includes the entire BARF0 ORF with an additional 105 N-




c25a RB2/BK1 RB3 RK1
Passaged NPC 4/4b 4/4 2/2 2/2
Biopsy
Primary-site NPC 14/17 7/7 7/7 7/7
Secondary-site NPC 5/5 ND ND ND
BL 1/1 1/1 1/1 1/1
Parotid carcinoma 1/1 1/1 1/1 1/1
Cell line
B95-8 (type III LCL) 1 1 1 1
Raji (type III BL) 1 1 1 1
Akata (type I BL) 1 1 1 1
Mutu (type I BL) 1 1 1 1
a RT-PCR and hybridizations to detect specific cDNAs were performed with
oligo(dT)-primed total RNA, using primers and probes as shown in Fig. 3A and
described in Materials and Methods. The passaged NPCs used for c25a and
RB2/BK1 PCR were C15, C17, C18, and C19. C15 and C18 were used for RB3
and RK1 PCR. ND, not determined.
b Number expressing alternately spliced BamHI A mRNA/number examined.
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terminal residues and would encode a protein of 30 kDa. This
ORF contains a strongly hydrophobic region at the amino termi-
nus (Leu-Val-Val-Val-Ala-Gly-Met-Val-Ala-Val-Ala), which
closely resembles an endoplasmic reticulum-targeting signal
peptide sequence. Signal peptides have been identified in nu-
merous secretory and transmembrane proteins, and although
no stringent consensus sequence exists, they contain character-
istic features to which the putative signal peptide of RK-
BARF0 conforms (30). The hydrophobic core of 10 to 12 aa,
located at the amino terminus, most frequently includes a high
proportion of alanine, leucine, and valine residues. Further,
alanine residues in the middle of the core frequently occur in
two- or three-residue symmetrical repeat elements (in RK-
BARF0, Val-Ala-X-X-X-Ala-Val). The hydrophobic core of
RK-BARF0 is immediately followed by a stretch of positively
charged residues. This configuration may be sufficient to cause
stop-translocation of the nascent peptide, resulting in a type III
(N terminus extracytoplasmic, C terminus cytoplasmic) inte-
gral membrane protein (20, 48).
The BARF0 and RK-BARF0 ORFs are unusual in that the
polyadenylation signal in each is internal to the ORF (59 of the
stop codon), and it has been suggested that this arrangement is
inconsistent with translation of these ORFs (15). Functional
internal polyadenylation signals have been reported for other
genes, however, including the chicken growth hormone recep-
tor gene and polyomavirus middle T antigen (PyMT) gene (27,
37). In this study, the internal polyadenylation signal of
BARF0 has been shown to direct heterogeneous 39-end pro-
cessing. Approximately 25% of the transcripts contain the
complete BARF0 ORF, while the remainder are truncated and
do not include the stop codon. The 39 RACE analysis has also
indicated that transcripts containing the RK-BARF0 ORF are
similarly processed. Heterogeneous 39-end processing has
been reported for several genes, including the mouse ribo-
somal protein L30, luteinizing hormone receptor, bovine pro-
lactin, and hepatitis B virus surface antigen gene (14, 40, 42,
47). Interestingly, the internal polyadenylation signal of PyMT
also directs heterogeneous 39-end processing, and about 50%
of the transcripts truncate the ORF. It is not known if the
truncated PyMT transcripts are translated (37).
This study has demonstrated that a subset of BamHI A
mRNAs of 4.8 kb and larger initiate 59 to a previously reported
start site. The cDNAs containing these sequences were un-
spliced in exon I and were detected by Northern blotting as a
small proportion of the total BamHI A transcripts. Multiple
start sites have also been identified for the EBV EBNA
mRNAs, which initiate from two distinct promoters (Cp and
Wp) for transcripts encoding EBNA-2, -3A, -3B, -3C, and -LP
and from three promoters (Cp, Wp, and Fp) for transcripts
encoding EBNA-1 (2, 38, 39, 41, 44, 45).
The BamHI A transcripts encode a number of ORFs that
are formed by alternate splicing, and this feature is also shared
by other EBV latent-gene mRNAs. Alternate splicing creates a
subset of EBNA transcripts that contain the initiation codon
for the EBNA-LP ORF (35, 39, 45). In addition, the EBNA
transcripts utilize common 59 exons but are distinctly spliced to
incorporate the various EBNA ORFs in the 39 exons (17). The
BamHI A mRNAs, in contrast, are 39-end coterminal but are
distinctly cleaved to incorporate the BARF0 ORF stop codon
in a subset of the transcripts.
Previous studies have demonstrated expression of the
BamHI A mRNAs in NPC and lymphoid samples, but the
structures of these transcripts in various tissues had not been
well characterized. In NPC, the relative level of BamHI A
transcription is significantly higher than in BL lines or in LCLs,
and the detection by RT-PCR of several, distinct cDNAs in
numerous NPC samples indicates that this elevated expression
consists of many mRNA species. In lymphoid cells displaying
both type I and type III gene expression, the pattern of tran-
scription was shown to be similarly complex. The distinct
cDNA structures were also demonstrated in parotid carcinoma
and BL in vivo, for which BamHI A transcription has not been
previously reported.
The data presented in this study demonstrate additional
levels of transcriptional complexity in the BamHI A mRNAs.
Multiple start sites and heterogeneous 39-end processing sug-
gest potential levels of regulation for the ORFs encoded by
these alternately spliced transcripts. The BARF0 ORF is con-
tained in all of these transcripts, and ORFs spanning multiple
exons are created by distinct splicing patterns. These splicing
patterns were detected in a wide range of EBV-infected cell
types, suggesting that these ORFs may be a significant com-
ponent of BamHI A expression in vivo. The heterogeneous
splicing of these transcripts may also serve as a regulatory
mechanism by conferring upon a particular ORF a favorable
context for translation by internal ribosomal loading. Although
genetic studies have shown that the complete sequences
spanned by the BamHI A mRNAs can be deleted from the
virus without affecting lymphocyte transformation, these tran-
scripts may have an epithelial cell-specific function that is not
assayable by the existing in vitro models of infection (34). The
highly abundant expression of these transcripts in the latently
infected epithelial cells of NPC suggests that the additional
viral proteins potentially encoded by these RNAs are impor-
tant for epithelial infection in vivo.
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